Naproxen and sulindac in the treatment of osteoarthritis of the hip and knee.
Thirty patients with osteoarthritis of the hip or knee were entered into a double-blind, cross-over study of naproxen (750 mg/day) and sulindac (400 mg/day) both given in twice-daily regimens. Patients received each drug for four weeks. Both drugs produced improvements in the patients' overall condition. There were no statistically significant differences between the effects of the two drugs. There were few side-effects. Overall, both drugs proved beneficial and safe.
D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006621:Hip Joint; D006801:Humans; D007192:Indenes / Q000627:therapeutic use*; D007719:Knee Joint; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D011897:Random Allocation; D013467:Sulindac / Q000009:adverse effects / Q000627:therapeutic use*
D007192:Indenes; D013467:Sulindac; D009288:Naproxen